Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3033 |
|
| Actual shortage: | 243 (8%) | |
| Anticipated shortage: | 15 (0%) | |
| Avoided shortage: | 9 (0%) | |
| Resolved: | 2766 (91%) | |
Discontinuation Reports |
356 |
|
| To be discontinued: | 22 (6%) | |
| Discontinued: | 334 (94%) | |
| Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
29 (10%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2022-06-06 | 2022-08-11 | 162080 |
| APO-ALENDRONATE | 70MG | TABLET | Resolved | 2022-07-11 | 2022-08-11 | 164370 |
| APO-PERINDOPRIL | 4MG | TABLET | Resolved | 2022-05-27 | 2022-08-11 | 161451 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2022-07-19 | 2022-08-12 | 164882 |
| APO-GUANFACINE XR | 1MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-07-11 | 2022-08-12 | 164378 |
| APO-MEDROXY | 10MG | TABLET | Resolved | 2022-07-22 | 2022-08-12 | 165326 |
| APO-MIRTAZAPINE | 15MG | TABLET | Resolved | 2022-06-27 | 2022-08-12 | 163453 |
| APO-MIRTAZAPINE | 30MG | TABLET | Resolved | 2022-07-15 | 2022-08-12 | 164741 |
| APO-CANDESARTAN | 4MG | TABLET | Actual shortage | 2022-08-12 | 2022-08-12 | 166589 |
| APO-CANDESARTAN | 8MG | TABLET | Actual shortage | 2022-08-12 | 2022-08-12 | 166592 |
| APO-CANDESARTAN | 16MG | TABLET | Actual shortage | 2022-08-12 | 2022-08-12 | 166595 |
| APO-ATORVASTATIN | 80MG | TABLET | Resolved | 2022-07-11 | 2022-08-19 | 164373 |
| APO-NAPRO-NA | 275MG | TABLET | Resolved | 2022-06-06 | 2022-08-22 | 162077 |
| APO-CITALOPRAM | 40MG | TABLET | Resolved | 2022-07-11 | 2022-08-22 | 164367 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2022-04-08 | 2022-08-24 | 158348 |
| APO-LEVETIRACETAM | 250MG | TABLET | Resolved | 2022-07-15 | 2022-08-24 | 164710 |
| APO-LEVETIRACETAM | 500MG | TABLET | Resolved | 2022-06-27 | 2022-08-24 | 163448 |
| APO-LEVETIRACETAM | 750MG | TABLET | Resolved | 2022-08-19 | 2022-08-24 | 167416 |
| APO-NAPRO-NA DS | 550MG | TABLET | Resolved | 2022-07-15 | 2022-08-24 | 164744 |
| APO-ABIRATERONE FILM COATED TABLETS | 500MG | TABLET | Resolved | 2022-07-22 | 2022-08-26 | 165311 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| IBUPROFEN CAPLETS | 400MG | TABLET | Discontinued | 2019-01-07 | 2019-07-13 | 71451 |
| IBUPROFEN CAPLETS | 200MG | TABLET | Discontinued | 2019-07-12 | 2019-07-13 | 89135 |
| IBUPROFEN | 200MG | TABLET | Discontinued | 2019-01-07 | 2019-07-22 | 71439 |
| APO-DICLO | 50MG | TABLET (ENTERIC-COATED) | Discontinued | 2019-08-07 | 2019-08-07 | 91117 |
| APO-DICLO | 50MG | TABLET (ENTERIC-COATED) | Discontinued | 2018-09-07 | 2019-08-08 | 60420 |
| APO NAPROXEN TAB 125MG | 125MG | TABLET | Discontinued | 2018-09-08 | 2019-08-08 | 60663 |
| APO-ACETAMINOPHEN EXTRA STRENGTH | 500MG | TABLET | Discontinued | 2019-01-02 | 2019-08-08 | 70807 |
| APO-ROSUVASTATIN | 40MG | TABLET | Discontinued | 2018-09-08 | 2019-08-08 | 60772 |
| APO-OXAZEPAM | 10MG | TABLET | Discontinued | 2018-09-08 | 2019-08-30 | 60675 |
| APO-TAMOX TAB 20MG | 20MG | TABLET | Discontinued | 2018-09-10 | 2019-09-12 | 61050 |
| APO-RABEPRAZOLE | 10MG | TABLET (ENTERIC-COATED) | Discontinued | 2018-02-23 | 2019-09-12 | 40805 |
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94446 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94449 | ||
| APO-GLIMEPIRIDE | Discontinued | 2019-09-20 | 2019-09-20 | 94452 | ||
| APO-SOLIFENACIN | 5MG | TABLET | Discontinued | 2019-03-11 | 2019-09-20 | 78272 |
| APO-SOLIFENACIN | 10MG | TABLET | Discontinued | 2019-03-11 | 2019-09-20 | 78269 |
| APO-CLINDAMYCIN | 150MG | CAPSULE | Discontinued | 2019-11-11 | 2019-11-11 | 98363 |
| APO-HYDROCHLOROTHIAZIDE | Discontinued | 2019-11-26 | 2019-11-26 | 99653 | ||
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-ALENDRONATE | 10MG | TABLET | To be discontinued | 2018-09-07 | 2019-12-20 | 60163 |